SEHK:1530Biotechs
Will Weakness in 3SBio Inc.'s (HKG:1530) Stock Prove Temporary Given Strong Fundamentals?
3SBio (HKG:1530) has had a rough week with its share price down 3.7%. But if you pay close attention, you might gather...
SEHK:6998Biotechs
Genor Biopharma Holdings (HKG:6998) adds HK$105m to market cap in the past 7 days, though investors from a year ago are still down 42%
Genor Biopharma Holdings Limited ( HKG:6998 ) shareholders should be happy to see the share price up 12% in the last...
SEHK:2162Biotechs
Individual investors invested in Keymed Biosciences Inc. (HKG:2162) copped the brunt of last week's HK$3.5b market cap decline
Key Insights Significant control over Keymed Biosciences by individual investors implies that the general public has...
SEHK:2696Biotechs
Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
SEHK:2181Biotechs
Insiders were the key beneficiaries as Mabpharm Limited's (HKG:2181) market cap rises to HK$2.1b
Key Insights Mabpharm's significant insider ownership suggests inherent interests in company's expansion The top 2...
SEHK:9995Biotechs
Retail investors who have a significant stake must be disappointed along with institutions after RemeGen Co., Ltd.'s (HKG:9995) market cap dropped by HK$1.1b
Key Insights RemeGen's significant retail investors ownership suggests that the key decisions are influenced by...
SEHK:6826Biotechs
Are Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Shanghai Haohai Biological Technology (HKG:6826) has had a rough three months with its share price down 13%. We...
SEHK:8158Biotechs
Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
SEHK:1877Biotechs
Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
It's not a stretch to say that Shanghai Junshi Biosciences Co., Ltd.'s ( HKG:1877 ) price-to-sales (or "P/S") ratio of...
SEHK:9926Biotechs
There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price
You may think that with a price-to-sales (or "P/S") ratio of 33.9x Akeso, Inc. ( HKG:9926 ) is a stock to avoid...
SEHK:9966Biotechs
Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch
Alphamab Oncology ( HKG:9966 ) shareholders that were waiting for something to happen have been dealt a blow with a 40...
SEHK:2197Biotechs
Institutions along with retail investors who hold considerable shares inClover Biopharmaceuticals, Ltd. (HKG:2197) come under pressure; lose 16% of holdings value
Key Insights Significant control over Clover Biopharmaceuticals by retail investors implies that the general public has...
SEHK:1801Biotechs
Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price
Innovent Biologics, Inc.'s ( HKG:1801 ) price-to-sales (or "P/S") ratio of 11.9x might make it look like a buy right...
SEHK:1672Biotechs
Ascletis Pharma (HKG:1672) dips 10% this week as increasing losses might not be inspiring confidence among its investors
Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...
SEHK:9969Biotechs
Is InnoCare Pharma (HKG:9969) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
SEHK:1530Biotechs
Earnings growth of 3.1% over 5 years hasn't been enough to translate into positive returns for 3SBio (HKG:1530) shareholders
Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. To...
SEHK:1167Biotechs
We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
SEHK:9995Biotechs
RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected
It's not a stretch to say that RemeGen Co., Ltd.'s ( HKG:9995 ) price-to-sales (or "P/S") ratio of 24.5x right now...
SEHK:1228Biotechs
CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings
To the annoyance of some shareholders, CANbridge Pharmaceuticals Inc. ( HKG:1228 ) shares are down a considerable 26...
SEHK:6660Biotechs
AIM Vaccine Co., Ltd.'s (HKG:6660) stock price dropped 3.1% last week; private companies would not be happy
Key Insights AIM Vaccine's significant private companies ownership suggests that the key decisions are influenced by...
SEHK:9926Biotechs
Investors in Akeso (HKG:9926) have seen solid returns of 231% over the past year
Akeso, Inc. ( HKG:9926 ) shareholders might be concerned after seeing the share price drop 19% in the last quarter. But...
SEHK:1877Biotechs
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Shanghai Junshi Biosciences is HK$46.95 based on 2 Stage Free Cash Flow to...
SEHK:690Biotechs
Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)
Uni-Bio Science Group Limited ( HKG:690 ) announced strong profits, but the stock was stagnant. We did some digging...
SEHK:2616Biotechs
CStone Pharmaceuticals Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
CStone Pharmaceuticals ( HKG:2616 ) Full Year 2022 Results Key Financial Results Revenue: CN¥481.4m (up 98% from FY...